Shanghai, China, March 27, 2025 – Asieris Pharmaceuticals (Stock Code: 688176.SH), a global innovative pharmaceutical company focused on genitourinary tumors and women’s health, announced today that its subsidiary Baylink Biosciences Inc. (Baylink) will present two latest research achievements in poster format at the 2025 American Association for Cancer Research (AACR) Annual Meeting, held from April 25th to 30th in Chicago, USA. The poster details are as follows:
Abstract: A linker platform for antibody drug conjugates (ADCs): expanding the therapeutic window
Poster number：7463
Section：45
Poster Board Number：8
Session Date and Time: April 30, 2025, 9:00 AM – 12:00 PM
Abstract: Preclinical evaluation of BLB-101, a topoisomerase-inhibitor-based anti-CLDN6/9 antibody-drug conjugate featuring a proprietary hydrophilic linker
Poster number：1578
Section：15
Poster Board Number：27
Session Date and Time: April 28, 2025, 9:00 AM – 12:00 PM
The AACR Annual Meeting is one of the world’s largest and most prestigious cancer research conferences. Selection for presentation at the AACR Annual Meeting signifies that these research findings have been recognized and endorsed by AACR’s expert committee, demonstrating their significant potential to advance disease treatment and prevention. The abstracts are now available on the official AACR website.
About Asieris
Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. We strive to improve human health to preserve patient’s dignity. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.
Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.
